Israeli drugmaker says TEV-408, an anti-IL-15 antibody designed for quarterly dosing, improved skin pigmentation in an early-stage study and will move into Phase 2b development later this year | Read More in ynet – Culture
IDF investigating shooting in Kiryat Arba, HebronUS strikes southern Iran in response to Iranian attacks in the Strait of HormuzHaredi protests against Jerusalem Light Rail continue, reports of over NIS 400 million in damageUK summons senior Iranian diplomat over stabbing of Iran International journalist in London
‘Unconditional support’ US support for Netanyahu was a mistake, Rahm Emanuel says
Nigel Farage resigns from parliament to force ‘people vs establishment’ vote
How a TV regulator became the center of Israel’s constitutional crisis
Yoseph Haddad prepares political run as parties court himIDF investigating shooting in Kiryat Arba, HebronUS strikes southern Iran in response to Iranian attacks in the Strait of HormuzHaredi protests against Jerusalem Light Rail continue, reports of over NIS 400 million in damageWhy we fall for emotionally unavailable peopleUK summons senior Iranian diplomat over stabbing of Iran International journalist in London
